Cancer treatment by radiotherapy in Kenya started in the 1970s when a Cobalt-60 EBRT treatment machine was donated to KNH by the Karolinska Institute through a Swedish and Kenya Government partnership. One Radiation Oncologist and a Medical Physicist, also from Sweden, initiated the cancer treatment program and started training the local personnel.

Based on 2002 data from the Nairobi Cancer Registry, of all the cancers registered, breast cancer accounted for 23.3%, cervical cancer 20%, and prostate cancer 9.4% [1].

Cervical, breast, and prostate cancer have continued to be the most prevalent types of cancer in the country, even to date [2] and in agreement with other published data [3]. Similar to prostate cancer, the majority of our cancer patients only seek treatment when the disease is already advanced, contributing to high mortality rates [4].

Screening of cervical and breast cancer can be done in the majority of the County and Sub-county hospitals, but the screening programs lack organization, and their availability is now widely known, and thus are less beneficial to the needy population.

The only public cancer treatment center in Kenya had been operational since the 1970’s. Recently (2009-2021), six private and three public hospitals have opened modern facilities for cancer care and treatment (Table 1).

The major workload, however, remains at the public institutions where the costs for cancer care and treatment are affordable compared to the private hospitals. Seven other proposed public cancer centers are also close to offering radiotherapy services, as well (Table 1).

Although systemic therapy and surgery are also part of cancer treatment here in Kenya, radiotherapy is an essential part of the treatment and is divided into external beam radiation therapy (EBRT) and brachytherapy.

Based on a past publication on the history of cancer and treatment in Kenya, [2], both EBRT by use of Co-60 teletherapy machine and brachytherapy treatments of thyroid cancer using I-131 oral solution, gynecological cancer treatment, and even Strontium/Yttrium-90 eye plaque treatment started in the early 1970’s. In the early 1980s, the first Kenyan radiation oncologists, medical physicists, and therapy radiographers began training through International Atomic Energy Agency (IAEA) fellowship programs, and the cancer treatment activities continued to grow.

The theme of the study was to assess statistics of cancer patients treated by radiotherapy in Kenya before 2019. Kenyatta National Hospital (KNH) and The Nairobi Hospital (TNH), both in Nairobi, were the two cancer centers selected as representative of the other cancer centers in the country that had radiotherapy equipment and were actively in practice. The only public hospital (KNH) with radiotherapy treatment facilities in Kenya was selected, and the second one (TNH) was a private hospital.

The major reason why the above two cancer treatment centers were chosen for the study is that during the beginning of the study in 2013, these were the only centers with facilities and actively involved in radiotherapy treatment, the others had not yet begun. The public hospital (KNH) was the main referral and teaching hospital and received all public referrals and consultations for cancer treatment across the country.

A data compilation, analysis, and evaluation process was conducted at two cancer treatment centers in Kenya; Kenyatta National Hospital (KNH) and The Nairobi Hospital (TNH), public and private hospitals, respectively, were selected for the study.

The main equipment for cancer treatment by EBRT at KNH included only two Co-60 machines and one Elekta linear accelerator (linac). There was also one Nucletron HDR brachytherapy treatment unit that accommodated Iridium-192 sources. A conventional 2D treatment technique using Co-60 was used for EBRT treatments before the linac was acquired, and calculations of the tumor dosage for the treatment were based on ICRU Report No. 24 [5]. Radiotherapy treatment data collected at this hospital were for treatments using the Co-60 beams only.

The private cancer center was the second institution where cancer treatment data were collected and compiled. Radiotherapy treatment here started in 2012 with the use of two Varian Linacs (2300D series) for EBRT that provide 6 MV and 15 MV photon beams. Superficial tumors and keloids can also be treated here with the Linac electron beams (6, 9, 12, and 15 MeV).

3D CRT technique was used for EBRT treatments, and all captured data for the patients treated represent treatment with the technique alone.

There is also one Varian HDR brachytherapy machine at TNH and a BK Medical Systems machine for Iodine-125 permanent seeds ultrasound-guided prostate brachytherapy. For the first two years of treatment, we managed to treat 37 prostate cancer patients with this procedure.

In summary, an assessment of the types of equipment available at different operational and proposed cancer centers in the country was done as presented in Table 1.

Treatment of thyroid cancer by the use of I-131 capsules is also practiced in both cancer centers. This is a brachytherapy treatment procedure, but thyroid cancer can also be treated by EBRT depending on the clinical diagnosis.

Further to the above, a total of 1210 different types of cancer patients being treated at the two cancer treatment centres were also investigated and analysed for their ages and gender. At Kenyatta National Hospital (KNH), 125 cervical cancer patients treated by use of Co-60 gamma radiation were assessed. The other 1085 types of cancer patients were being treated at The Nairobi Hospital with Linear Accelerator photon beams for EBRT (except the prostate cancer patients). These were breast (291), cervical (399), lung (39), rectum (58), oesophagus (248), and prostate (60) cancer. Our investigation applied hospital-based data for the patients undergoing radiotherapy treatment from the two hospitals. For each type of cancer, the number of patients against their age was plotted on a graph, Figure 2. Also, it was clearly demonstrated in Figure 3 that, of all the assessed cancer types, each of them appeared at a different mean age.

Since the data that was created or retrieved from patient files was not complicated, analysis and data compilation did not present any challenges.

Currently, the majority of the operational cancer centers here now treat EBRT patients with three Dimensional Conformal Radiotherapy (3D CRT) treatment technique by use of linear accelerator photon and electron energy beams, but the initial public hospital also treats some cancer cases with two dimensional (2D) conventional technique using Co-60 beams.

Two centers now use intensity modulation radiotherapy (IMRT) treatment technique while one center treats some cancer patients with Volumetric Modulated Arc Therapy (VMAT) External Beam technique.

Prostate cancer was initially treated by EBRT before 2017 when the private center began prostate brachytherapy treatment with I-125 ultrasound-guided permanent seed implants.

The major advantages of this treatment technique for prostate cancer have been characterized by Butler [6] as a one-time outpatient procedure, continuous low dose-rate treatment, dose conformity, and sparing of normal tissue, among other reasons [6]. Also, I-125 permanent seeds brachytherapy treatment has been reported to be comparable to radical prostatectomy and to control the prostate PSA 10 years longer than EBRT [7] [8]. Prostate cancer screening can also be done in county hospitals, but its popularity is lower compared to screening for cervical and breast cancer.

The majority of our patients come with “high grade” prostate cancer currently managed by a combination of an initial brachytherapy treatment with I-125 permanent seed implants (110 Gy) followed by an EBRT “boost” dose of 45 Gy. For those patients diagnosed with clinically localized prostate cancer, radical prostatectomy, brachytherapy, and EBRT treatments are recommended.

The protocol for the treatment of cervical cancer by radiotherapy at the two cancer centers is a combination of 50 Gy of EBRT dose (2 Gy per day, 5 days a week) followed after one month by a brachytherapy “boost” dose of 16 Gy (8 Gy weekly for two weeks), 21 Gy (7 Gy weekly for three weeks) or 24 Gy (8 Gy weekly for three weeks). The radiotherapy dose would be supplemented by systemic therapy, as well. Breast cancer is treated here by a combination of surgery, EBRT, or systemic therapy depending on the stage and the extent of the disease.

Treatment of breast cancer by interstitial brachytherapy is not common at our two centers.

The patients’ information and treatment data for the study were retrieved by the author between 2013 and 2019. During this period, the Research & Ethics Committees of Kenyatta National Hospital, University of Nairobi, and The Nairobi Hospital had granted the relevant approvals for the study to be undertaken. The patients included were those on radiotherapy treatment and did not include palliative or distant metastatic treatment from the primary site.

Cancer treatment data at the two institutions indicate a continuous increase in the numbers of cancer patients treated by radiotherapy annually [2], and Figure 1.

Although the increase may be a contribution to the increasing population and the growing adoption of unhealthy lifestyles [9], it is true that there is some increase in cancer awareness now compared to past years.

The trends of the graphs of cancer treatment data for different types of cancer in both centers were similar and some cancers were more common compared to others [6], Figure 1. Cervical cancer was the most common cancer treated by radiotherapy at the two centers followed by breast and prostate cancer, respectively.

An assessment study of TNH cancer patients treated with EBRT (2982), Ir-192 Brachytherapy (1881), I-131 thyroid treatment (69), I-125 Prostate therapy (37), was done to compare the different treatments. Table 2 shows the results in the percentage of the respective treatments.

Radiotherapy EBRT had the highest percentage of treatments (60%) followed by Ir-192 brachytherapy treatments (38%), I-131 thyroid treatment (1.4%), and prostate brachytherapy (0.7%) treatment with I-125 permanent seed implants respectively.

For the age analysis of the cancer patients treated, a combined graph of all the number of patients against their age was plotted in Figure 2 and shows the mean age of each type of cancer. Also, a combined graph (Figure 4) of the three most common types of cancer (cervical, breast, and prostate) was plotted and clearly demonstrate that female cervical and breast cancers are presenting in patients at younger mean age (46 - 50 years) compared to the male prostate cancer appearing in older patients at a mean age of 61 - 65 years.

A summary of Figure 2 was clearly demonstrated in Figure 3 that, of all the assessed cancer types, each of them appeared at a different mean age.

Although cancer treatment data at the two centers was not done extensively, a comparison of age data for cervical cancer patients treated was done and the results were analyzed graphically in Figure 5. The mean age for the cervical cancer patients treated at the two centers was between 46 - 50 years.

Cancer treatment data at the two institutions indicate a continuous increase in the numbers of cancer patients treated by radiotherapy annually [2], “and Figure 1”. The trends of the graphs of cancer treatment data for different types of cancer in both centers were similar and some cancers were more common compared to others [6], Figure 1. Cervical cancer was the most common cancer treated by radiotherapy at the two centers followed by breast and prostate cancer, respectively

Results of analysis of TNH patients treated by different modalities showed that EBRT accounted for 60% of all radiotherapy patients treated compared to 40% of those treated by brachytherapy (Ir-192 treatments, I-125 prostate permanent seeds, and I-131 thyroid capsules),

The plotted data of ages of cervical, breast, and prostate cancer patients treated at TNH (Figure 4) clearly demonstrate that female cervical and breast cancers are presenting in patients at younger mean age (46 - 50 years) compared to the male prostate cancer appearing in older patients at a mean age of 61 - 65 years. This is consistent with past published data, [4] [7] [11]. Figure 5 compared the ages of cervical cancer patients treated at the two hospitals and had similar mean ages (46 - 50 years), which may suggest that the patients treated at different hospitals in the country were normally distributed.

Figure 2 and Figure 3 plotted graphs of all the cancer types against their ages as a clear demonstration that each type of cancer appeared at a unique mean age and that the female cervical and breast cancers appeared at younger ages than their male esophageal and prostate cancers.

Patients who need radiotherapy for cancer treatment have been on the increase annually. This may be due to the rising population, limited cancer awareness, and the growing adoption of unhealthy lifestyles, as well as access to limited cancer treatment facilities. Cervical, breast, and prostate cancer are among the most frequent types in Kenya, just like in other developing countries.

Results of analysis of TNH patients treated by different modalities showed that EBRT accounted for 60% of all radiotherapy patients treated compared to 40% of those treated by brachytherapy (Ir-192 treatments, I-125 prostate permanent seeds, and I-131 thyroid capsules), The female cervical and breast cancer patients had an overall mean age of 46 - 50 years, quite young compared to the male prostate cancer patients who had a mean age of 61 - 65 years. Cervical cancer was identified as the most commonly treated by radiotherapy in Kenya with 37% - 41% of all cancers treated by EBRT.

Our proposed solutions to the observed challenges would include strengthening cancer awareness in Kenya through social media to include the more remote areas, a well-organized national cancer screening program for the most common cancers, such as cervical, prostate, and breast cancer, need to be implemented and would require funding.

A formalized National Cancer Registry [16] [17] should be implemented through the Ministry of Health, so that future planning of cancer treatment and the relevant infrastructure can be possible. This is now long overdue, several institutions and individuals have shown substantial effort in compiling their own data due to the unavailability of a formalized national registry.

The Government should adopt the “Abuja declaration” that proposed a 15% budget for healthcare for every African country’s annual budget.

Training of relevant personnel needs to be strengthened and expanded to cover the referring 47 county hospitals.

Thus, Socio-economic factors, the organization of healthcare systems, and a limited workforce have been identified as some of the barriers to the provision of proper radiotherapy services in the country.

I acknowledge my Institutions’ Ethics and Research Committee (Kenyatta National Hospital, University of Nairobi, and The Nairobi Hospital) for accepting and allowing me to do my Ph.D. research project at the institutions.

The authors declare no conflicts of interest regarding the publication of this paper.

Ndonye, P.K. and Tagoe, S.N.A. (2022) Current Status of Radiotherapy Services in Kenya. Journal of Cancer Therapy, 13, 218-233. https://doi.org/10.4236/jct.2022.134018